Table 5.
Effect of Garidisan on IFN-r, IL-4, and IFN-r/IL-4 in peripheral blood (M ± SEM, n = 6).
| Group | IFN-r (ng/L) | IL-4 (ng/L) | IFN-r/IL-4 |
|---|---|---|---|
| Normal control | 1414.14 ± 118.10### | 97.26 ± 3.01### | 14.53 ± 0.88### |
| UC model | 814.95 ± 86.41∗∗∗ | 166.32 ± 10.60∗∗∗ | 4.91 ± 0.55∗∗∗ |
| Low-dose Garidisan | 1070.78 ± 92.88∗∗∗### | 133.01 ± 7.81∗∗∗### | 8.05 ± 0.44∗∗∗### |
| Moderate-dose Garidisan | 1075.57 ± 121.05∗∗∗### | 122.17 ± 8.93∗∗∗### | 8.79 ± 0.58∗∗∗### |
| High-dose Garidisan | 1247.53 ± 91.27∗∗### | 136.97 ± 9.09∗∗∗### | 9.14 ± 0.91∗∗∗### |
| Sulfasalazine | 1165.63 ± 50.22∗∗∗### | 112.27 ± 7.58∗∗### | 10.44 ± 1.06∗∗∗### |
| Bupiyichangwan | 1297.87 ± 66.35∗### | 135.42 ± 13.50∗∗∗### | 9.65 ± 0.97∗∗∗### |
∗ P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 compared with normal controls. P < 0.05, P < 0.01, and ###P < 0.001 compared with the UC model group.